Nav: Home

Mice immunized with synthetic horsepox protected against vaccinia virus

January 19, 2018

Immunization with a synthetic horsepox virus offers mice similar protection to immunization with vaccinia virus against a lethal dose of vaccinia, according to a study published January 19, 2018 in the Open Access journal PLOS ONE by Ryan Noyce from the University of Alberta, Canada, and colleagues.

The vaccinia virus (VACV) used as a live vaccine protects against smallpox, but is associated with serious side effects. As VACV shows close similarities to the horsepox virus (HPXV), Noyce and his colleagues tested whether HPXV could offer an alternative to the live VACV vaccine.

The only identified specimen of HPXV is unavailable for investigation and it is believed that the HPXV virus has been eradicated. Using similar techniques already used to generate synthetic polio and influenza viruses, the team successfully generated a chimeric HPXV virus using chemically-synthesized DNA fragments based on the previously published HPXV and VACV genomes. They then used cell culture to activate the virus.

The researchers found that the chimeric HPXV produced fewer extracellular virus particles and was less virulent than VACV. Mice intranasally infected with chimeric HPXV developed similar levels of protective antibodies to mice inoculated with VACV, but had less severe reactions. When challenged with lethal dosages of VACV, mice previously immunized with chimeric HPXV were protected against severe illness.

The virus synthesized in the present study is less virulent than the modern strain of vaccinia virus, and therefore does not cause an immediate biosafety or biosecurity risk. However, the authors acknowledge that the generation of the first synthetic poxvirus presents risks of future misuse. The study demonstrates that the technological capacity exists. However, the work also highlights how synthetically engineered viruses might have potential in improving vaccines.

This work was conducted with the knowledge and support of the University of Alberta's biosafety program. Research facilities involved in the project are compliant with the Canadian Biosafety Standard and are properly registered with the Public Health Agency of Canada under the Human Pathogens and Toxins Act. In recognition of the biosecurity risks, the authors also reported their findings to the World Health Organization (WHO) Advisory Committee of Variola Virus Research.

PLOS is committed to the widespread dissemination of research and to responsible publication standards. To this end, PLOS maintains a Dual Use Research of Concern Committee consisting of in-house and external experts. The committee assessed the risks and benefits of publication of the present study and supported publication on the basis that it does not provide new information specifically enabling the creation of a smallpox virus, but uses known methods, reagents and knowledge that have previously been documented and used in the synthesis of other viruses. That the DNA synthesis in this study was performed by a commercial third-party service is not only a testament to the present state of technology, but also underlines the safeguards and risk assessments that need to be considered for studies of this type. PLOS supports an open debate about the associated biosafety and biosecurity concerns.
In your coverage please use this URL to provide access to the freely available article in PLOS ONE:

Citation: Noyce RS, Lederman S, Evans DH (2018) Construction of an infectious horsepox virus vaccine from chemically synthesized DNA fragments. PLoS ONE 13(1): e0188453.

Funding: This work was performed under a research agreement with Tonix Pharmaceuticals. The funder played a role in the formulation of the project, the decision to publish, and preparation of the manuscript.

Competing Interests: We have read the journal's policy and the authors of this manuscript have the following competing interests: DHE and RDN provide consultation services to Tonix Pharmaceuticals Ltd. SL is the co-founder, CEO and chairman of Tonix Pharmaceuticals Ltd. A US patent application (Synthetic chimeric poxviruses; Application No.: 62/434,794; first provisional filed November 2, 2016) has been filed on behalf of the Governors of the University of Alberta and Tonix Pharmaceuticals claiming the three authors as co-inventors. This does not alter our adherence to PLOS ONE policies on sharing data and materials. The DNAs and reconstructed HPXV strains can be provided upon request. Please direct all such enquiries to Dr. S. Lederman, c/o Tonix Pharmaceuticals.


Related Immunization Articles:

Global immunization impact constrained by outdated vaccine delivery systems, researchers say
Outdated vaccine supply and distribution systems are delaying and limiting the impact that vaccines have on safeguarding people's health.
A new approach against Salmonella and other pathogens
Researchers from MIT and UC Irvine have developed a way to immunize against microbes that invade the gastrointestinal tract, including Salmonella, the leading cause of foodborne illness in the US.
Pitt-developed program improves adult immunization rates at primary care offices
A University of Pittsburgh-developed program successfully boosts vaccination rates in adult patients seen at primary care offices, two recent studies demonstrated.
Immunization with bacteria promotes stress resilience, coping behaviors in mice
Injections of the soil bacterium Mycobacterium vaccae promote stress resilience and improve coping behaviors in mice, according to a new study led by researchers at University of California San Diego School of Medicine and University of Colorado Boulder.
Immunization with bacteria promotes stress resilience, coping behaviors in mice
Injections of the soil bacterium Mycobacterium vaccae (M. vaccae NCTC 11659) promote stress resilience and improve coping behaviors in mice, according to a new study led by the University of Colorado Boulder.
Immunization rates climb when pediatricians have easy access to vaccination records
Exchange of immunization data between a centralized city immunization registry and provider electronic health records led to significant improvements in pediatric immunization coverage, a reduction in over-immunization for adolescents, and increased completeness of immunization records, according to a latest study.
African countries announce integration of meningitis vaccine into childhood immunization programs
Global vaccine experts and officials from all 26 African 'meningitis belt' countries will convene in Ethiopia next week in advance of the Ministerial Conference on Immunization to celebrate one of Africa's biggest public health achievements -- the introduction of a vaccine that in five years of use has protected more than 235 million people in 16 countries, nearly eliminating meningitis A disease on the continent.
Expanding use of vaccines could save up to $44 for every dollar spent, study suggests
Vaccinations, long recognized as an excellent investment that saves lives and prevents illness, could have significant economic value that far exceeds their original cost, a new study from researchers at the Johns Hopkins Bloomberg School of Public Health has found.
Whooping cough booster vouchers don't boost immunization rates of caregivers
A team of researchers evaluated the feasibility and impact of different interventions aimed at increasing the number of Tdap vaccinated caregivers.
ACP receives four-year federal award to increase adult immunization rates
The American College of Physicians was awarded a $1,002,884 Cooperative Agreement from the Centers for Disease Control and Prevention to increase immunization rates in the United States.

Related Immunization Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Digital Manipulation
Technology has reshaped our lives in amazing ways. But at what cost? This hour, TED speakers reveal how what we see, read, believe — even how we vote — can be manipulated by the technology we use. Guests include journalist Carole Cadwalladr, consumer advocate Finn Myrstad, writer and marketing professor Scott Galloway, behavioral designer Nir Eyal, and computer graphics researcher Doug Roble.
Now Playing: Science for the People

#529 Do You Really Want to Find Out Who's Your Daddy?
At least some of you by now have probably spit into a tube and mailed it off to find out who your closest relatives are, where you might be from, and what terrible diseases might await you. But what exactly did you find out? And what did you give away? In this live panel at Awesome Con we bring in science writer Tina Saey to talk about all her DNA testing, and bioethicist Debra Mathews, to determine whether Tina should have done it at all. Related links: What FamilyTreeDNA sharing genetic data with police means for you Crime solvers embraced...